Patent intelligence · US
US 9220676
Injectable in-situ crosslinked hydrogel and methods of making and using thereof
Injectable in-situ crosslinked hydrogel and methods of making and using thereof
Patent details — US 9220676
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 29, 2015
- Expiration
- Dec 24, 2035
- Claims
- 21
- CPC classes
- A61K, A61K9/0019, A61K9/0024, A61P
Quick answer
US 9220676 (Injectable in-situ crosslinked hydrogel and methods of making and using thereof) is held by BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.. Status: granted. Granted Dec 29, 2015. Expires Dec 24, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K9/0019, A61K9/0024, A61P, A61P31/00, A61P35/00
More from BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9220676?
US 9220676 (Injectable in-situ crosslinked hydrogel and methods of making and using thereof) is held by BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD.. Status: granted. Granted Dec 29, 2015. Expires Dec 24, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9220676?
BIOREGEN BIOMEDICAL (CHANGZHOU) CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9220676 expire?
Our index shows an expiration date of Dec 24, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.